Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

Acute Myeloid Leukemia
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Gastric Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Gynecologic Cancers
Head and Neck Cancers
Hematology
Hepatocellular Carcinoma
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Myeloproliferative Neoplasms
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Soft Tissue Sarcoma
Thyroid Cancers

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

Biosimilars MORE >>

Pegfilgrastim Biosimilar Approved by FDA
November 06, 2018
Pegfilgrastim-cbqv (CHS-1701; Udencya), a pegfilgrastim (Neulasta) biosimilar, has been granted approval by the FDA for patients with cancer receiving myelosuppressive chemotherapy.
Read more >>
Expert Panel Discusses the Financial and Economic Impact of Biosimilars
November 01, 2018
Trastuzumab Biosimilar Candidate Shows Promise in Early-Stage Breast Cancer
August 30, 2018
Second Filgrastim Biosimilar Granted FDA Approval
July 24, 2018
PFS With MYL-1401O Regimen Similar to Trastuzumab at 48 Weeks in HER2-Positive Metastatic Breast Cancer
June 08, 2018

VideosMORE >>

Impact of Biosimilars on Oncology

Latest JournalAll Journals >>

Evolving Paradigms Non-Small Cell Lung Cancer
Evolving Paradigms
Dr. Langer Discusses the Prevalence of Patients With Non-Driver NSCLC
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
Nonbiomarker, Nonsquamous NSCLC: Diagnosis, Statistics, Staging, and Testing
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLC
Emerging Treatment Strategies in Nonsquamous NSCLC
MORE >>
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.